Amgen Inc. (AMGN) Stock Analysis
Temp Headwind edge
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $328.81 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: Puerto Rico.
Amgen is one of the largest independent biotechnology companies, discovering, developing, manufacturing, and commercializing human therapeutics in a single operating segment with presence in approximately 100 countries. Revenue comes from product sales including Repatha, ENBREL,... Read more
Sell if holding. Analyst target reached at $328.81 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: Puerto Rico. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.5/10, high confidence.
Passes 5/7 gates (clean insider activity, no SEC red flags, news boost earnings 0.80, earnings proximity no date, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicPuerto Rico10-K Item 1A: 'We perform a substantial majority of our commercial manufacturing activities at our facility in the U.S. territory of Puerto Rico'
Material Events(8-K, last 90d)
- 2026-04-22Item 5.02LOWEVP David M. Reese retiring as CTO effective June 30, 2026. Responsibilities redistributed to EVPs Bradner, Gordon, and Griffith effective June 1, 2026. No successor named as CTO.SEC filing →
- 2026-01-30Item 1.02MEDIUMAmgen and Kyowa Kirin Co., Ltd. agreed to terminate their License and Collaboration Agreement dated June 1, 2021. Termination effective upon receipt of regulatory approval. No reason cited beyond mutual agreement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $328.81 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: Puerto Rico. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $315.68. Score 5.5/10, high confidence.
Take-profit target: $352.25 (+7.8% upside). Prior stop was $315.68. Stop-loss: $315.68.
Concentration risk — Geographic: Puerto Rico; Analyst target reached - limited upside remaining; Leverage penalty (D/E 6.2): -1.5.
Amgen Inc. trades at a P/E of 24.1 (forward 14.8). TrendMatrix value score: 5.5/10. Verdict: Sell.
43 analysts cover AMGN with a consensus score of 3.5/5. Average price target: $353.
What does Amgen Inc. do?Amgen is one of the largest independent biotechnology companies, discovering, developing, manufacturing, and...
Amgen is one of the largest independent biotechnology companies, discovering, developing, manufacturing, and commercializing human therapeutics in a single operating segment with presence in approximately 100 countries. Revenue comes from product sales including Repatha, ENBREL, Otezla, TEPEZZA, and IMDELLTRA. A substantial majority of commercial manufacturing occurs at its Puerto Rico facility.